Sugi Predict

Sugi Predict / Compounds / Sinitrodil

Sinitrodil

Sinitrodil

SCHEMBL503115

O=C1c2ccccc2OCN1CCO[N+](=O)[O-]

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ ALDH1A1 P00352 5/20 0.34
▸ HTT P42858 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ MITF O75030 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ PRMT5 O14744 2/20 0.33
▸ WDR77 Q9BQA1 2/20 0.33
▸ AGTR1 P30556 1/20 0.32
▸ RAB9A P51151 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ PTGS2 P35354 1/20 0.30
▸ MAOB P27338 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ SIRT1 Q96EB6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sinitrodil SCHEMBL31066546 1.00 TSHR (0.34) TSHRPKMALDH1A1HTTLMNA
SCHEMBL9165703 0.90 PTGS2 (0.35) PTGS2MAOB
SCHEMBL8635639 0.83 CASP1 (0.39) ALDH1A1RAB9A
SCHEMBL9166368 0.83 ACHE (0.32) ALDH1A1LMNAPTGS2MAOB
SCHEMBL8641204 0.83 ACHE (0.38) ALDH1A1
SCHEMBL8637170 0.83 MAPT (0.35) ALDH1A1MAPTRAB9A
SCHEMBL6436979 0.83 ALDH1A1 (0.36) TSHRALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL9173014 0.83 MAOB (0.35) MAPTPTGS2MAOB
SCHEMBL8638777 0.83 MAOA (0.38) MAOB
SCHEMBL9167754 0.83 ALDH1A1 (0.36) ALDH1A1LMNASMN1; SMN2AGTR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115188-A1 METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR INTRA-CELLULAR THERAPIES, INC. (US) 2026-04-30 — — US claimed
US-12478623-B2 Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor INTRA-CELLULAR THERAPIES, INC. (US) 2025-11-25 — — US claimed
EP-4277592-A1 TOPICAL COMPOSITION Liliger Ltd (IL) 2023-11-22 — — EP claimed
US-20220362241-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. 2022-11-17 — — US claimed
EP-4034119-A1 NOVEL METHODS Intra-Cellular Therapies, Inc. (US) 2022-08-03 — — EP claimed
WO-2022153308-A1 TOPICAL COMPOSITION RICH PSC LTD. (IL) 2022-07-21 — — WO claimed
US-20210386944-A1 GAS-EVOLVING COMPOSITIONS AND CONTAINER AND DELIVERY SYSTEMS SANOTIZE RESEARCH DEVELOPMENT CORP. (CA) 2021-12-16 — — US claimed
WO-2021062307-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. (US) 2021-04-01 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20130338118-A1 COMPOUNDS FOR TREATMENT OF HEART FAILURE SOLVOTRIN INNOVATIONS LIMITED (IE) 2013-12-19 — — US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20050181066-A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency ALTANA PHARMA AG (DE) 2005-08-18 — — US claimed
EP-1501605-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA Pharma AG (DE) 2005-02-02 — — EP claimed
US-20030216384-A1 Composition and method for treating hypertension NORTHERN SYDNEY AREA HEALTH SERVICE 2003-11-20 — — US claimed
WO-2003090870-A1 NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY ALTANA PHARMA AG (DE) 2003-11-06 — — WO claimed
EP-0490183-B1 Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity ITALFARMACO SPA (IT) 1995-04-19 — — EP claimed
US-5189034-A Vasodilating, antianginal agents ITALFARMACO S.P.A. (IT) 1993-02-23 — — US claimed
EP-0490183-A1 Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity ITALFARMACO S.p.A. (IT) 1992-06-17 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210386944-A1 GAS-EVOLVING COMPOSITIONS AND CONTAINER AND DELIVERY SYSTEMS GMPS, SQOR, GSS TSHR 4725/4885PKM 1673/4885ALDH1A1 807/4885
US-20220362241-A1 NOVEL METHODS HTR2A, HTR2C, HTR2B TSHR 382/4885PKM 3420/4885ALDH1A1 752/4885
US-20130338118-A1 COMPOUNDS FOR TREATMENT OF HEART FAILURE MMP9, NOS2, MMP1 TSHR 1768/4885PKM 1816/4885ALDH1A1 2466/4885
US-20260115188-A1 METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR HTR2C, DRD2, HTR2A TSHR 118/4885PKM 2001/4885ALDH1A1 669/4885
US-12478623-B2 Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor HTR2A, HTR2C, HTR5A TSHR 450/4885PKM 2121/4885ALDH1A1 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.